Liver Function's impact on drug breakdown under microscope

NCT ID NCT04271488

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how mild and moderate liver problems change the way the body handles a single dose of the drug tasurgratinib. Researchers will compare 18 people with stable liver impairment to healthy volunteers matched by age, weight, race, and gender. The goal is to understand how the liver processes the drug, which helps guide safe dosing for patients with liver issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Eisai Trial Site #1

    RECRUITING

    Mintato-ku, Tokyo, Japan

  • Eisai Trial Site #2

    RECRUITING

    Yuhu, Oita Prefecture, Japan

  • Eisai Trial Site #3

    RECRUITING

    Bukyo-ku, Tokyo, Japan

  • Eisai Trial Site #4

    TERMINATED

    Kurume, Fukuoka, Japan

  • Eisai Trial Site #5

    RECRUITING

    Kofu, Yamanashi, Japan

  • Eisai Trial Site #6

    RECRUITING

    Hakata, Fukuoka, Japan

  • Eisai Trial Site #7

    RECRUITING

    Kyoto, Japan

  • Eisai Trial Site #8

    RECRUITING

    Shinjuku-ku, Tokyo, Japan